Bivalirudin vs DSIP
Overview
Bivalirudin is primarily a cardiovascular peptide, while DSIP is used for sleep & recovery.
This page compares Bivalirudin and DSIP across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | DSIP | |
|---|---|---|
| Category | Cardiovascular | Sleep & Recovery |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | 100-300 mcg |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | before bed |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Improved deep sleep, stress reduction, recovery enhancement, pain reduction |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Very well-tolerated, possible grogginess |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while DSIP falls under Sleep & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. DSIP: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). DSIP is typically dosed at 100-300 mcg (before bed).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and DSIP has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and DSIP?
- Bivalirudin is primarily a cardiovascular peptide, while DSIP is used for sleep & recovery. Bivalirudin is FDA-approved for one or more indications, whereas DSIP is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is DSIP used for?
- Delta sleep-inducing peptide.
- Can you take Bivalirudin and DSIP together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and DSIP has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or DSIP FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. DSIP is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- DSIP — full monograph: mechanism, research, dosing & references